Jeffrey W. Albers, Director at Spyre Therapeutics, Inc. (SYRE), sold 300 shares at $36.43 ($11K) on 2024-10-25, disclosed to the SEC on 2024-10-28.
Scheduled sale ($11k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| KYMR | SELL | 2025-10-14 | $296K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |